Amgen vs Intel: Founders, CEOs and History
Amgen was founded in 1980 by George B. Rathmann, William K. Bowes Jr. and is led by Robert A. Bradway. Intel was founded in 1968 by Robert Noyce, Gordon Moore and is led by Lip-Bu Tan.
Company facts
Founders
Amgen
George B. Rathmann
Amgen, originally incorporated as Applied Molecular Genetics, was founded in 1980 not by a single scientist, but by a calculated syndicate of venture capitalists and academics trying to commercialize the brand-new science of recombinant DNA.
William K. Bowes Jr.
William K. Bowes Jr. Was the venture capital strategist whose vision catalyzed Amgen's formation.
Intel
Robert Noyce
Intel possesses the most well-known founding story in the entire history of Silicon Valley, famously founded by the effective, rebellious engineers who essentially invented the fundamental architecture of the modern digital world.
Gordon Moore
Gordon Moore co-founded Intel and served as a key technical leader, CEO, and chairman during the company's formative decades. His most important contribution was turning transistor scaling into a corporate operating philosophy.
CEOs and their tenures
Amgen
- George B. Rathmann1980–1988
Chief Executive Officer
George Rathmann, a physical chemist who had run research and development at Abbott Laboratories, was named Amgen's first chief executive in 1980 and worked from a small trailer so that laboratory space could go to scientists.
Source - Gordon M. Binder1988–2000
Chief Executive Officer
Gordon Binder joined Amgen as chief financial officer in 1982 and led its June 1983 initial public offering.
Source - Kevin W. Sharer2000–2012
Chief Executive Officer
Kevin Sharer joined Amgen in 1992 as president and chief operating officer and became chairman and chief executive in 2000.
Source - Robert A. Bradway2012–present
Chairman and Chief Executive Officer
Robert Bradway became chief executive on May 23, 2012, succeeding Kevin Sharer as the fourth CEO in Amgen's history, and added the chairmanship at the start of 2013.
Source
Intel
- Andy Grove1987–1998
CEO
Grove turned Intel into the dominant PC processor supplier; revenue grew from about $1.9B in 1987 to over $26B in 1998. His book 'Only the Paranoid Survive' became a management classic.
Source - Pat Gelsinger2021–2024
CEO
Gelsinger rebuilt Intel's process roadmap toward 18A, but capital spending outpaced revenue. After a $18.8B net loss in 2024 and a dividend suspension, the board pushed him out in December 2024.
Source - Lip-Bu Tan2025–present
Chief Executive Officer
Tan reframed Intel around customer commitments and cost discipline rather than building capacity ahead of demand. By Q2 2026 Intel had beaten guidance for several straight quarters and posted its fastest revenue growth in more than 15 years.
Source
Timeline: Amgen and Intel side by side
1968Intel
Intel Founded
Robert Noyce and Gordon Moore founded Intel.
1971Intel
4004 Microprocessor
Intel introduced the 4004, one of the first commercial microprocessors.
1980Amgen
Applied Molecular Genetics is incorporated
Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.
1983Amgen
Nasdaq listing and the erythropoietin clone
Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.
1984Amgen
Kirin-Amgen joint venture formed
Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.
1985Amgen
G-CSF cloned, leading to Neupogen
While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.
1985Intel
386 Processor
Intel strengthened the x86 franchise that later dominated PCs.
1989Amgen
FDA approves Epogen
The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.
1991Amgen
Neupogen approved, giving Amgen a second franchise
The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.
1991Amgen
Amgen wins the erythropoietin patent fight
On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.
1993Intel
Pentium Processor Launched
Intel introduced the Pentium processor in 1993.
2001Amgen
FDA approves Aranesp, the longer-acting EPO
Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.
2002Amgen
US$16 billion Immunex acquisition brings Enbrel in-house
Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.
2006Intel
Core Architecture
Intel revived product leadership with the Core architecture.
2010Amgen
Prolia and XGEVA create the bone health franchise
The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.
2019Amgen
US$13.4 billion purchase of Otezla from Celgene
Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.
2020Amgen
Amgen joins the Dow Jones Industrial Average
Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.
2021Intel
IDM 2.0 Announced
Intel announced a strategy to expand manufacturing and foundry capabilities.
2021Intel
Pat Gelsinger Becomes CEO
Pat Gelsinger became Intel chief executive in February 2021.
2023Amgen
US$27.8 billion Horizon Therapeutics acquisition closes
Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.
2024Amgen
Imdelltra becomes the first T-cell engager for small cell lung cancer
The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.
2025Amgen
VESALIUS-CV extends the Repatha case to primary prevention
In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.
2025Intel
Lip-Bu Tan Becomes CEO
Lip-Bu Tan became CEO and reset the turnaround agenda around execution, cost, and focus.
2025Intel
$52.853B Revenue
Intel reported $52.853B in revenue and a $267M net loss attributable to Intel.
2025Intel
U.S. Government Takes 9.9% Stake
The U.S. government bought 433.3 million Intel shares at $20.47 for $8.9 billion, becoming the largest shareholder.
2025Intel
Nvidia Invests $5 Billion
Nvidia agreed to invest $5 billion in Intel and co-develop x86 PC and data-center products.
2025Intel
Altera Majority Sold
Intel closed the sale of 51% of Altera to Silver Lake on September 12, 2025.
2026Amgen
Medicare price setting reaches Enbrel and Otezla
Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.
2026Intel
Q2 Revenue Up 25%
Intel reported $16.1 billion in Q2 2026 revenue, its fastest growth in more than 15 years.
Acquisitions
Amgen
- Horizon Therapeutics plc2023$27.8B
- ChemoCentryx, Inc.2022$3.7B
- Five Prime Therapeutics2021$1.9B
- Celgene Otezla Business2019$13.4B
- Onyx Pharmaceuticals, Inc.2013$10.4B
- DeCODE Genetics2012$415M
Intel
- Moovit2020$900M
- Habana Labs2019$2B
- Mobileye2017$15.3B
- Altera2015$16.7B
- McAfee2011$7.7B
Questions about Amgen vs Intel
Who is the CEO of Amgen Inc. and Intel Corporation?
Amgen Inc. is led by Robert A. Bradway and Intel Corporation is led by Lip-Bu Tan. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Amgen Inc. founded vs Intel Corporation?
Intel Corporation was founded in 1968 — 12 years before Amgen Inc., which was founded in 1980. Intel Corporation's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Amgen Inc..
How many employees does Amgen Inc. have compared to Intel Corporation?
Amgen Inc. employs approximately 31,500 people, while Intel Corporation employs approximately 85,100. Intel Corporation has the larger workforce at 85,100 employees, compared to Amgen Inc.'s 31,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Amgen Inc. and Intel Corporation headquartered?
Both Amgen Inc. and Intel Corporation are headquartered in United States, meaning they operate under the same primary regulatory and tax environment.
Who founded Amgen Inc. and Intel Corporation?
Amgen Inc. was founded by George B. Rathmann, William K. Bowes Jr.. Intel Corporation was founded by Robert Noyce, Gordon Moore.
Which company has a longer operating history — Amgen Inc. or Intel Corporation?
Intel Corporation has been operating for approximately 58 years, making it the more established of the two companies. Amgen Inc. has been in operation for around 46 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Amgen vs Intel overview